RTP Mobile Logo

LeukemiaTT115/Audio

OVERVIEW OF ACTIVITY

IASLCImmunotherapy15

TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

Lung Cancer Update, Issue 1, 2015

OVERVIEW OF ACTIVITY

GrandRoundsCLL15

TARGET AUDIENCE
This activity is intended for medical oncologists, hematologists and other healthcare providers involved in the treatment of chronic lymphocytic leukemia (CLL).

COCMM15/3

OVERVIEW OF ACTIVITY

LCUTT115/Audio

OVERVIEW OF ACTIVITY

iJournal Club - Lung Cancer: 2015

OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease with broad-reaching impact on public health, as it accounts for 14% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In 2015, it is estimated that 221,200 new cases will be diagnosed and 158,040 deaths will occur from the disease. In addition, only 16% of all patients with lung cancer are alive 5 years or more after diagnosis, despite currently available therapies.

GrandRoundsLung15

TARGET AUDIENCE
This activity is intended for medical oncologists and other healthcare providers involved in the treatment of lung cancer.

ASCOLung15

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of non-small cell lung cancer (NSCLC).

ASCOBreast15

TARGET AUDIENCE
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of breast cancer (BC).

RTPODBreast215

TARGET AUDIENCE
This activity is intended for medical and radiation oncologists, breast and general surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

RTPODBreast2015

TARGET AUDIENCE
This activity is intended for medical and radiation oncologists, breast and general surgeons, hematology-oncology fellows and other healthcare providers involved in the treatment of breast cancer.

OVERVIEW OF ACTIVITY

ASCOHem15

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hematologic cancers.

OVERVIEW OF ACTIVITY
Hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders (eg, myelodysplastic syndromes, myeloproliferative diseases) stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that approximately 162,020 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2015 and 56,630 individuals will die from these diseases.

LeukemiaTT115/Video

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

GITumorPanel

TARGET AUDIENCE
This activity is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal, gastric and pancreatic cancer.

OVERVIEW OF ACTIVITY
Cancer of the colon and rectum is the fourth most frequently diagnosed cancer and the second most common cause of death among all neoplasms in the United States, accounting for approximately 8% of all cancer deaths. Although individually less frequently encountered, the collection of noncolorectal gastrointestinal (GI) cancers account for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined.